CRITICS study – ASCO 2016

Share This Post

The 2016 American Conference of Clinical Oncology (ASCO) is about to be held in Chicago as one of the most talked about academic conferences in the field of oncology. The new research and progress made by each ASCO conference are the focus of everyone’s attention.

Marcel Verheij scholars from the Netherlands will soon announce the results of a phase III multi-center clinical study (CRITICS) from Europe at the 2016 ASCO conference. For gastric cancer patients who have undergone neoadjuvant chemotherapy, postoperative chemotherapy and postoperative chemoradiation are combined There was no significant difference in survival rate. The study will be presented orally at 8:00 am on June 6, 2016.

The study included a total of 788 patients with operable gastric cancer in the three countries of the Netherlands, Sweden and Denmark, all of whom underwent 3 cycles of ECC / EOC (eprubicin + cisplatin / oxaliplatin + capecitabine) Treatment, divided into chemotherapy group (n = 393, continue with another 3 cycles of ECC / EOC treatment) or chemotherapy group (n = 395,45 Gy + cisplatin + capecitabine) after operation, with an average follow-up of 50 months, mainly The study endpoint was overall survival (OS), and the secondary endpoints were disease-free survival (DFS), safety, and quality of life. The results showed that the 5-year OS in the chemotherapy group was 41.3%, and the 5-year OS in the chemotherapy group was 40.9%. There was no significant difference between the two groups. In terms of safety, it is mainly hematology and gastrointestinal adverse events.

The main cure for gastric cancer is radical surgical resection, but in Western countries, the long-term survival of advanced gastric cancer is poor (about 25%), and local recurrence occurs in about 80% of patients. Postoperative chemoradiation and perioperative chemotherapy have been shown to have survival benefits, but continued chemotherapy after neoadjuvant chemotherapy is inconclusive compared with postoperative chemoradiation.

The results of the CRITICS study suggest that for postoperative gastric cancer patients, there may be no significant difference in survival benefit between postoperative chemotherapy and postoperative chemoradiation.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy